This website is intended only for healthcare professionals outside the UK and Australia.
All our specialties
Based on your interest
All our specialties
MEDICALLY
Congresses
Stay up to date with the latest scientific information from international medical congresses.
All our specialties
Diseases
Explore disease information across relevant specialties
All our specialties
External site
By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.
Gastrointestinal cancers, including hepatocellular carcinoma, colorectal, esophageal and gastric cancers, are among the most commonly diagnosed cancers worldwide and current global statistics rank these malignancies as the leading causes of cancer deaths worldwide.
As 5-year survival rates for GI cancers are among the lowest among major tumor types, they comprise some of the world’s largest areas of unmet need in Oncology.
IMbrave150 is a global Phase III, multicentre, open-label study of 501 people with unresectable HCC who have not received prior systemic therapy. People were randomised 2:1 to receive the combination of atezolizumab and bevacizumab or sorafenib. Results of IMbrave150 have been published in New England Journal of Medicine (NEJM).
This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.